The BIOVF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOVF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BIOVF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BIOVF Detailed Price Forecast - CNN Money||View BIOVF Detailed Summary - Google Finance|
|View BIOVF Detailed Summary - Yahoo! Finance||View BIOVF Stock Research & Analysis - Zacks.com|
|View BIOVF Trends & Analysis - Trade-Ideas||View BIOVF Major Holders - Barrons|
|View BIOVF Call Transcripts - NASDAQ||View BIOVF Breaking News & Analysis - Seeking Alpha|
|View BIOVF Annual Report - CompanySpotlight.com||View BIOVF OTC Short Report - OTCShortReport.com|
|View BIOVF Fundamentals - TradeKing||View BIOVF SEC Filings - Bar Chart|
|View Historical Prices for BIOVF - The WSJ||View Performance/Total Return for BIOVF - Morningstar|
|View the Analyst Estimates for BIOVF - MarketWatch||View the Earnings History for BIOVF - CNBC|
|View the BIOVF Earnings - StockMarketWatch||View BIOVF Buy or Sell Recommendations - MacroAxis|
|View the BIOVF Bullish Patterns - American Bulls||View BIOVF Short Pain Metrics - ShortPainBot.com|
|View BIOVF Stock Mentions - StockTwits||View BIOVF Stock Mentions - PennyStockTweets|
|View BIOVF Stock Mentions - Twitter||View BIOVF Investment Forum News - Investor Hub|
|View BIOVF Stock Mentions - Yahoo! Message Board||View BIOVF Stock Mentions - Seeking Alpha|
|View Insider Transactions for BIOVF - SECform4.com||View Insider Transactions for BIOVF - Insider Cow|
|View BIOVF Major Holdings Summary - CNBC||View Insider Disclosure for BIOVF - OTC Markets|
|View Insider Transactions for BIOVF - Yahoo! Finance||View Institutional Holdings for BIOVF - NASDAQ|
|View BIOVF Stock Insight & Charts - FinViz.com||View BIOVF Investment Charts - StockCharts.com|
|View BIOVF Stock Overview & Charts - BarChart||View BIOVF User Generated Charts - Trading View|
Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
Posted on Monday November 12, 2018
STOCKHOLM, Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares.
Invitation - Presentation of Sobi's Q3 2018 Results
Posted on Tuesday October 23, 2018
STOCKHOLM , Oct. 23, 2018 /PRNewswire/ -- On 31 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018. Financial analysts and media are invited ...
What Does Swedish Orphan Biovitrum AB (publ)’s (STO:SOBI) Ownership Structure Look Like?
Posted on Thursday September 13, 2018
If you want to know who really controls Swedish Orphan Biovitrum AB (publ) (STO:SOBI), then you’ll have to look at the makeup of its share registry. Institutions often own sharesRead More...
Sobi™ Completes Acquisition of the Global Rights for Emapalumab From Novimmune
Posted on Thursday August 23, 2018
STOCKHOLM, August 23, 2018 /PRNewswire/ -- Following approvals from relevant competition authorities, Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has completed the acquisition of the perpetual global rights to emapalumab from Novimmune SA. That Sobi had entered into an exclusive licence agreement for the acquisition of the perpetual global rights to emapalumab was announced on 20 July 2018. Emapalumab is a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis (HLH), developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.